医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promedica International and Dr. Agarwal’s Eye Hospitals Form Strategic Alliance

2019年06月28日 PM09:00
このエントリーをはてなブックマークに追加


 

NEWPORT BEACH, Calif.

Promedica International (PMI) and Dr. Agarwal’s Eye Hospitals (AEH) have formed a new partnership to conduct clinical trials in India, which they announced at the OCTANe Ophthalmology Technology Summit. PMI and AEH emphasized that this alliance will enable them to collaboratively enroll and manage clinical studies in an expanded patient population, while conforming with global and FDA qualification standards and regulations.

PMI, as a professional contract research organization based in the US, will lead in the design of studies that meet or exceed global Good Clinical Practice and medical quality standards. AEH, which is an international ophthalmic healthcare system, will provide clinical expertise and facility access in India.

With its extensive background in clinical research, PMI offers services that include project management, study management and monitoring, data management, statistical services, clinical quality assurance, medical writing and global regulatory support.

“For PMI, this partnership will initially augment our resources for enrollment and management of FDA clinical trials. At the same time, AEH gains the opportunity to significantly improve their quality and volume of clinical research with timely execution of studies,” said Shannon Stoddard, President/CEO of PMI. “Over the longer term, we believe this collaboration will enable both parties to build a global organization for conducting ophthalmic studies, and foster the development of proprietary models for multiple disease states,” said Ms. Stoddard.

“AEH and PMI are a winning combination because we share complementary goals and a vision of how to best deliver on the promise of clinical research,” said Dr. Ashvin Agarwal, Executive Director, Chief of Clinical Services at AEH. “Dr. Agarwal’s Eye Hospitals welcomes the opportunity to work with PMI because of their success and the brand they have built performing their clinical study services on a global level.”

About Promedica International

Promedica International (PMI) is a privately held corporation with headquarters in Costa Mesa, California. Founded in 1985, the Company provides specialized clinical research services to the medical device, biotech, and pharmaceutical industries. ISO 9001:2015 certified and servicing a range of medical specialties and therapeutic areas, PMI offers extensive experience in clinical study services, as well as flexibility in accommodating a variety of project requirements and budgets.

For more information, please visit www.promedica-intl.com.

About Dr. Agarwal’s Eye Hospitals

Founded in 1957 by Jaiveer Agarwal and his wife Tahira Agarwal in Chennai, India, AEH is a global ophthalmology hospital group that has been a pioneer in eye care services for more than six decades. AEH now comprises more than 75 centers across 11 countries and serves the eye care needs of millions of patients, world-wide.

In their flagship hospital in Chennai and in all of their hospitals in India and Africa, the treatments offered by AEH are standardized to meet global benchmarks. All medical practitioners in AEH centers have been certified by the core clinical team. The ethos of a constant and rigorous training and development process ensures knowledge transfer and skill advancement among the medical personnel throughout the institution.

Reliance on best-in-class biomedical technology and continuous quality improvement ensures that the treatments AEH provides are truly cutting-edge. AEH and its biomedical partners share a passion to raise the bar of medical innovation.

For more information, please visit www.dragarwal.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190628005036/en/

CONTACT

Khan Lau

714-460-7363, Ext 19

klau@promedica-intl.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 2019年台湾医疗科技展展商简介
  • Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover
  • Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies
  • LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
  • AJC Organized the ASEAN Services Trade Forum in Tokyo to Discuss the Emerging Demands for Health and Social Services in ASEAN and Its Investment Opportunities